基于的化合物作为脏和膀癌症治疗的候选药物 - - 一项系统性审查
Mónica Costa Cerqueira1, Ana Silva1, Sofia Martins Sousa1
1Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3Bs-PT Government Associate Laboratory, 4805-017 Guimarães, Portugal.
Bioorganic chemistry
|October 11, 2024
概括
化合物有望通过抑制癌细胞生长和增加对治疗的敏感性来治疗和膀癌症. 需要进一步的研究才能充分实现它们在泌尿病恶性瘤中的治疗潜力.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌 (RC) 和膀癌 (BC) 是显著的泌尿系统恶性瘤,发病率和死亡率不断增加.
- 药物耐药性和毒性在当前的RC和BC治疗中构成重大挑战.
- 烯是异环化合物,具有抗癌特性,可以使癌细胞对治疗重新敏感.
研究的目的:
- 系统地审查基于染色体的化合物对癌和膀癌的治疗潜力.
- 评估前临床 (体外,体内) 和临床证据,以评估在泌尿病恶性瘤中染色体的疗效.
主要方法:
- 在六个数据库中进行了全面的文献搜索.
- 编制了研究研究染色体化合物对抗脏和膀癌的研究.
- 分析了关于染色体效应的临床前和临床数据.
主要成果:
- 衍生物在体外显示出强大的抗癌活性,减少细胞活力,增殖,迁移和入侵.
- 在体内研究显示,瘤体积和体重在染色体治疗后降低.
- 有限的临床数据表明适度反应,包括RC患者的部分和客观反应.
结论:
- 化合物代表了一个有前途的支架,用于开发用于脏和膀癌的新疗法.
- 染色体家族提供了潜在的候选药物,以克服泌尿癌治疗中的耐药性和毒性问题.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
151
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
151